A factual overview of FDA-approved therapies, active clinical trials, regulatory developments, and what patients should know. Independent resource — not medical advice.
Stem cell research and therapy in the United States remain one of the most promising yet tightly regulated fields in regenerative medicine. The FDA oversees all approvals, emphasizing safety and efficacy through rigorous clinical trials. As of early 2026, only a specific set of stem cell-based treatments are fully FDA-approved — mostly for blood and immune disorders.
Most applications for conditions like orthopedic injuries, neurodegenerative diseases, or autoimmune disorders are still experimental and can only be accessed through structured clinical trials registered on platforms like ClinicalTrials.gov. The field is maturing, with the FDA having approved over three dozen cell and gene therapies total, and more decisions expected in the first half of 2026.
The FDA maintains a curated list of Approved Cellular and Gene Therapy Products. Key approved stem cell-related therapies include:
Hematopoietic Stem Cell Transplants (HSCT) — The foundational approved use. Blood-forming stem cells from bone marrow or cord blood treat leukemias, lymphomas, sickle cell disease, and other blood disorders. Multiple cord blood products (e.g., Omisirge/omidubicel) are FDA-approved.
Ryoncil (remestemcel-L) — The first FDA-approved mesenchymal stromal cell (MSC) therapy and first off-the-shelf allogeneic cell therapy. Approved December 2024 for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients two months and older.
Encelto (revakinagene taroretcel) — Approved March 2025. The first-ever therapy for idiopathic macular telangiectasia type 2 (MacTel). An encapsulated cell therapy implant that secretes ciliary neurotrophic factor directly into the eye.
Casgevy & Lyfgenia — Combined cell and gene therapies approved for sickle cell disease, using patient-derived stem cells that are genetically modified and reinfused. Landmark approvals in the gene-editing space.
Important: Just because a condition appears on an approved-therapies list doesn't mean any stem cell product can treat it. Only specific FDA-approved products matched with specific indications have clearance. There is no FDA approval for treating orthopedic conditions (arthritis, back pain, tendinitis) with stem cells.
The FDA continues to balance innovation with patient safety. Key regulatory mechanisms accelerating the field include:
RMAT (Regenerative Medicine Advanced Therapy) designation gives promising candidates special FDA engagement and accelerated review. Fast Track, Breakthrough Therapy, and Priority Review designations also apply to qualifying stem cell products. Multiple BLA (Biologics License Application) decisions are expected in the first half of 2026, including Kresladi for LAD-I (PDUFA March 28, 2026) and Orca-T for hematologic malignancies (PDUFA April 6, 2026).
Some states (e.g., Florida, Montana) have passed laws expanding access to certain autologous (patient's own cells) stem cell therapies under "Right to Try" or medical freedom frameworks. However, federal FDA oversight remains dominant — these state laws do not override the requirement for FDA approval of biological products.
The U.S. stem cell therapy market is projected to grow from approximately $6.75 billion in 2025 to an estimated $21 billion by 2035, driven by advances in iPSC technology, cell and gene therapy convergence, and growing manufacturing capability.
Several high-profile clinical trials are active or launching in 2026. These represent the frontier of legitimate stem cell research in the United States:
Funded by a ~$12M CIRM grant, UC Irvine is set to launch a first-in-human trial in mid-2026 testing a stem cell therapy in early-stage Huntington's patients. A landmark moment for neurodegenerative disease research.
Aspen Neuroscience (ANPD001) is advancing personalized autologous iPSC-derived cell therapy for Parkinson's, with $115M in Series C funding. Related international trials at Kyoto University showed 4 of 6 patients had significant motor improvements at 24 months.
Capricor Therapeutics' allogeneic cardiosphere-derived cell therapy for DMD cardiomyopathy received Priority Review in 2025. The FDA issued a complete response letter; Capricor is addressing remaining issues with plans to resubmit.
The first iPSC-based therapy to enter a U.S. Phase III trial. Fertilo uses ovarian support cells derived from iPSCs to support ex vivo oocyte maturation, reducing the hormonal burden on patients. The technology has resulted in the first live birth.
An iPSC-derived therapy targeting retinitis pigmentosa and cone-rod dystrophy. Received FDA IND clearance in September 2024 — the first iPSC-based cell therapy to be clinically tested for primary photoreceptor diseases.
Dispatch Bio, in collaboration with Bristol Myers Squibb, is preparing a Phase 1 trial of DISP-10 — a two-component approach designed to overcome key barriers to CAR-T therapy in solid tumors. Expected to initiate in 2026.
UC Davis Health demonstrated that placenta-derived stem cells could safely repair birth defects before birth. All six treated infants in the trial showed reversed hindbrain herniation — a significant proof-of-concept for prenatal regenerative medicine.
Consumer Alert: The FDA has repeatedly warned against unproven "stem cell clinics" offering direct-to-consumer treatments. These clinics have been linked to serious adverse events including infections, blindness, and tumor formation. The FDA states: stem cell products have not been shown to be safe or effective for most orthopedic conditions, and no regenerative medicine therapy is approved for arthritis, back pain, knee pain, or similar complaints.
Legitimate stem cell therapy in the United States happens through FDA-approved products or structured clinical trials with regulatory oversight. If a clinic claims to offer an FDA-approved stem cell treatment for orthopedic, anti-aging, or general wellness conditions — ask for the specific FDA approval number. If they cannot provide one, proceed with extreme caution.
Ask your provider for the Investigational New Drug (IND) Application number if the treatment is part of a clinical trial. Search ClinicalTrials.gov to confirm the trial exists and is actively recruiting. You can also contact the FDA directly at 800-835-4709 to ask about a specific product's regulatory status.
For patients, families, and researchers looking for reliable information: